PMID-32409697 – BAM15 Reverses Diet-Induced Obesity and Insulin Resistance
Axelrod CL, King WT, Davuluri G, Noland RC, Hall J, Hull M, Dantas WS, Zunica ER, Alexopoulos SJ, Hoehn KL, Kirwan JP. "Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice." Nature Communications, 2020;11:2397.
Quick Reference
| Property | Value |
|---|---|
| PMID | 32409697 |
| DOI | 10.1038/s41467-020-16298-2 |
| Year | 2020 |
| Journal | Nature Communications |
| Study Type | Animal in vivo |
| Evidence Level | V |
| Sample | C57BL/6J mice, diet-induced obesity model |
| Peptide(s) Studied | BAM15 |
Key Findings
- Oral BAM15 is bioavailable and reverses diet-induced obesity in mice without altering food intake, lean body mass, body temperature, or biochemical/haematological markers of toxicity
- BAM15-treated mice showed significant decreases in body fat mass and hepatic steatosis (fatty liver)
- BAM15 decreased inflammatory lipid species (ceramides, diacylglycerols) in liver tissue
- Hyperinsulinemic-euglycemic clamp studies demonstrated that BAM15 improves insulin sensitivity in multiple tissue types (liver, skeletal muscle, adipose)
- BAM15 exhibited strong antioxidant effects, reducing reactive oxygen species generation
- Weight loss occurred through increased caloric expenditure (mitochondrial uncoupling) rather than appetite suppression — a fundamentally different mechanism from GLP-1 agonists or tesofensine
Study Design
Diet-induced obese C57BL/6J mice were treated with oral BAM15 or vehicle for multiple weeks. Body composition measured by EchoMRI. Comprehensive metabolic phenotyping included indirect calorimetry, food intake monitoring, body temperature telemetry. Insulin sensitivity assessed by gold-standard hyperinsulinemic-euglycemic clamp. Hepatic lipid profiles analyzed by lipidomics. Safety assessed via complete blood count and metabolic panels.
Limitations
- Mouse model only; no human pharmacokinetic or efficacy data
- Long-term safety beyond the study duration not assessed
- Thermoneutral housing conditions not used (may overestimate uncoupling effects in mice)
- Translation of effective dose to humans uncertain
Clinical Relevance
This is the landmark preclinical study establishing BAM15 as a viable anti-obesity therapeutic. The demonstration that BAM15 reduces body fat without affecting food intake, lean mass, or body temperature addresses the major safety concerns that plagued earlier mitochondrial uncouplers like DNP. The multi-tissue insulin sensitization and hepatic fat reduction suggest potential applications in metabolic syndrome and NAFLD/MASH beyond simple weight loss. Published in Nature Communications, this is the highest-impact BAM15 study to date.
Related
#research #animal-in-vivo #BAM15 #evidence-level-V